Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting

Anaesthesia

Volumn 65, Issue 10, 2010, Pages 996-1000

  Choi, E M ^c   Lee, M G ^c   Lee, S H ^a   Choi, K W ^c   Choi, S H ^b  

^a Anesthesia and Pain Research Institute   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; KETOROLAC; ONDANSETRON; REMIFENTANIL; ROCURONIUM; THIOPENTAL;

ABCB1 GENE; ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; DRUG EFFICACY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POSTOPERATIVE NAUSEA AND VOMITING;

ADULT; ANESTHESIA, GENERAL; ANTIEMETICS; CHOLECYSTECTOMY, LAPAROSCOPIC; FEMALE; GENOTYPE; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; ONDANSETRON; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; POSTOPERATIVE NAUSEA AND VOMITING; PROGNOSIS; TREATMENT OUTCOME;

EID: 77956520377     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2010.06476.x     Document Type: Article

References (21)

1. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999 91 : 693 700.
2. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs 2000 59 : 213 243.
3. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992 77 : 162 184.
4. Biedler A, Wermelt J, Kunitz O, et al. A risk adapted approach reduces the overall institutional incidence of postoperative nausea and vomiting. Canadian Journal of Anesthesia 2004 51 : 13 19.
5. Kovac AL, O'Connor TA, Pearman MH, et al. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled multicenter trial. Journal of Clinical Anesthesia 1999 11 : 453 459.
6. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996 97 : 2517 2524.
7. Babaoglu MO, Bayar B, Aynacioglu AS, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clinical Pharmacology and Therapeutics 2005 78 : 619 626.
8. Lee SS, Kim SY, Kim WY, et al. MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Therapeutic Drug Monitoring 2005 27 : 531 535.
9. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 2004 75 : 13 33.
10. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America 1987 84 : 7735 7738.
11. Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Therapeutic Drug Monitoring 1996 18 : 350 356.
12. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proceedings of the National Academy of Sciences of the United States of America 1997 94 : 2031 2035.
13. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neuroscience Letters 2002 327 : 173 176.
14. Yamamoto C, Murakami H, Koyabu N, et al. Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier. Journal of Pharmacy and Pharmacology 2002 54 : 1055 1063.
15. Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicology and Applied Pharmacology 1997 143 : 357 365.
16. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New England Journal of Medicine 2003 348 : 1442 1448.
17. Coulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clinical Pharmacology and Therapeutics 2006 79 : 316 324.
18. Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Current Opinion in Anesthesiology 2006 19 : 606 611.
19. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005 102 : 543 549.
20. Tang K, Ngoi SM, Gwee PC, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002 12 : 437 450.
21. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesthesia and Analgesia 2006 102 : 1884 1898.